Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li, Armando N Bastidas Torres, Erica B Wang, Melba Herrera, Tarek I Bandali, David M Kurtz, Youn H Kim, Michael S Khodadoust

Blood blood.2024024817.

https://doi.org/10.1182/blood.2024024817

Published: 2024

Includes: Supplemental data

Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Blood (2023) 142 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2023-184898

Published: 2023

Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2023-181459

Published: 2023

Journal Articles

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2023-190775

Published: 2023

Journal Articles

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Takeshi Sugio, Navika Shukla, Michael S Khodadoust, Monica Nesselbush, Koji Kato, Stefan K. Alig, Jan Boegeholz, Joseph Schroers-Martin, Mohammad Shahrokh Esfahani, Jurik A. Mutter, Andrea Garofalo, Soyeong Jun, Mark P. Hamilton, Cédric Rossi, Mari Olsen, Chih Long Liu, Koichi Akashi, Maximilian Diehn, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2023-180492

Published: 2023

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Michael S. Khodadoust, Eric Mou, Youn H. Kim

Blood (2023) 141 (7): 695–703.

https://doi.org/10.1182/blood.2020008241

Published: 2023

Journal Articles

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Tanaya Shree, Sarah Haebe, Debra K. Czerwinski, Erik Eckhert, Grady Day, Anuja Sathe, Susan M. Grimes, Matthew J Frank, Lauren S. Maeda, Ash A. Alizadeh, Ranjana H. Advani, Richard Hoppe, Steven R. Long, Brock Martin, Michael G. Ozawa, Michael S. Khodadoust, Hanlee P. Ji, Ronald Levy

Blood (2022) 140 (Supplement 1): 6450–6451.

https://doi.org/10.1182/blood-2022-167469

Published: 2022

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Navika D. Shukla, Joseph Schroers-Martin, Karan R. Kathuria, Brian Sworder, Stefan K. Alig, Matthew J Frank, David B. Miklos, Steven Coutre, Maximilian Diehn, Michael S. Khodadoust, Mark Roschewski, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 6403–6404.

https://doi.org/10.1182/blood-2022-165656

Published: 2022

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Eric Mou, Sebastian Fernandez-Pol, Shufeng Li, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 140 (Supplement 1): 6552–6553.

https://doi.org/10.1182/blood-2022-158610

Published: 2022

Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1301–1303.

https://doi.org/10.1182/blood-2022-165545

Published: 2022

Journal Articles

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Hitomi Hosoya, Mia Carleton, Kailee L Tanaka, Brian Sworder, Vanna Hovanky, George E Duran, Tian Y. Zhang, Michael S. Khodadoust, David B. Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David M. Kurtz

Blood (2022) 140 (Supplement 1): 1546–1548.

https://doi.org/10.1182/blood-2022-160370

Published: 2022

Journal Articles

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma

Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 139 (26): 3732–3736.

https://doi.org/10.1182/blood.2021014468

Published: 2022

Journal Articles

Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis

Joseph G Schroers-Martin, Joanne Soo, Gabriel Brisou, Florian Scherer, David M. Kurtz, Brian Sworder, Michael S. Khodadoust, Michael C. Jin, Agnès Bru, Chih Long Liu, Henning Stehr, Paolo Vineis, Yasodha Natkunam, Lauren R Teras, Joo Y. Song, Bertrand Nadel, Maximilian Diehn, Sandrine Roulland, Ash A. Alizadeh

Blood (2021) 138 (Supplement 1): 709.

https://doi.org/10.1182/blood-2021-151058

Published: 2021

Journal Articles

Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation

Tanaya Shree, Sarah Haebe, Debra K. Czerwinski, Grady Day, Anuja Sathe, Michael S. Khodadoust, Matthew J. Frank, Sara Beygi, Richard Hoppe, Steven R. Long, Brock Martin, Hanlee P. Ji, Ronald Levy

Blood (2021) 138 (Supplement 1): 3539.

https://doi.org/10.1182/blood-2021-154017

Published: 2021

Journal Articles

Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T Cell Lymphoma

Sara Beygi, Sebastian Fernandez-Pol, George Duran, Youn H. Kim, Michael S. Khodadoust

Blood (2021) 138 (Supplement 1): 1325.

https://doi.org/10.1182/blood-2021-153177

Published: 2021

Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, Michael S. Khodadoust, Javier Munoz, Paul A. Hamlin, Youn H. Kim, Ryan A. Wilcox, Manish R. Patel, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 622.

https://doi.org/10.1182/blood-2021-148352

Published: 2021

Journal Articles

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma

Tanaya Shree, Vishnu Shankar, Debra K. Czerwinski, Gladys Rodriguez, Sara Beygi, Joseph G Schroers-Martin, Ranjana Advani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, David M. Kurtz, Karen S. Corbelli, Etelka Gabriel, Alyssa M. Kanegai, Ash A. Alizadeh, Ronald Levy

Blood (2021) 138 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2021-153901

Published: 2021

NARROW

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma

Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis

Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation

Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T Cell Lymphoma

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only